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Abstracts
The Netherlands is striving to achieve national elimination of the hepatitis C virus (HCV) as one of the first countries
worldwide. The favorable HCV epidemiology with both low prevalence and incidence, together with access to care
and treatment, present excellent conditions to further build on towards this objective. The Dutch national plan on
viral hepatitis, introduced in 2016, defines targets in the HCV healthcare cascade and provides a structural
framework for the development of elimination activities. Since many different stakeholders are involved in HCV care
in the Netherlands, focus has been placed on micro-elimination initiatives as a pragmatic and efficient approach.
These numerous micro-eliminations projects have brought the Netherlands closer to HCV elimination. In the near
future, efforts specifically have to be made in order to optimize case-finding strategies and to successfully
accomplish the nationwide implementation of the registration and monitoring system of viral hepatitis mono-
infections, before this final goal can be reached. The upcoming years will then elucidate if the Dutch’ hands on
approach has resulted in sufficient progress against HCV and if the Netherlands will lead the way towards
nationwide HCV elimination.
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Background
Global elimination and eradication of the hepatitis C
virus (HCV) has become the ultimate endeavor and final
objective ever since the introduction of highly effective
direct-acting antivirals (DAAs). The once fatal disease
has thus been transformed into an infection that can
effortlessly be cured, provided that one has access to
care and therapy. Consequently, the World Health
Organization (WHO) even envisioned universal elimin-
ation of the HCV to be accomplished by the year 2030
[1]. To this end, the WHO urged countries to develop
and implement national policies on viral hepatitis.
However, the European Liver Patients Association
(ELPA) Hep-CORE study revealed that 14/27 countries
still did not have a written national plan for the manage-
ment of hepatitis C and / or hepatitis B (HBV) in 2016.
The Netherlands therefore subsequently introduced a
national plan on viral hepatitis in 2016 defining targets
for each step in the Dutch HCV healthcare cascade: 1)
awareness and prevention; 2) testing and diagnosis; 3)
linkage to care; 4) access to medication and 5) monitor-
ing and evaluation, in order to eventually achieve HCV
elimination [2]. National coordination of HCV elimin-
ation however is complicated by (regional) differences in
HCV patient subpopulations and the high number of
stakeholders involved in HCV care. Considering these
diversities, a uniform nationwide strategy targeting all
HCV patients is unlikely to be the key solution to finally
eliminate HCV. A more pragmatic approach would be
to apply more focus and work towards ‘micro-elimina-
tion’ in different HCV subpopulations (e.g., individuals
with HIV or hemophilia, (ever) injection drug users, mi-
grants from high endemic countries, health care workers,
prisoners). Micro-elimination, by way of targeting smaller
and clearly delineated HCV risk groups, allows for faster
and more efficient delivery of interventions. For this
reason, micro-elimination as a ‘bottom-up’ approach may
be a more feasible and efficient path to nationwide HCV
elimination [3]. Various stakeholders involved in HCV
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care have devoted their efforts to micro-elimination initia-
tives in the Netherlands, including: a) awareness cam-
paigns directed at (ever) injection drug users and migrants
but also health care workers; b) screening strategies in
risk-groups to find undiagnosed persons with HCV, as
recommended by the national Health Council [4]; c)
regional and nationwide retrieval projects of lost to
follow-up previously diagnosed patients; d) HCV health-
care pathways in addiction clinics and primary care to
promote and guide linkage to care; e) registry and close
monitoring of HCV subpopulations (registry of HIV/HCV
coinfected managed by the Dutch HIV monitoring foun-
dation and the hemophilia treatment center follows all
HCV patients with hemophilia). However, the success of
all (micro-) elimination efforts hinges on solid epidemio-
logic data on HCV prevalence and incidence in all HCV
risk groups. Adequate registration and monitoring is an
imperative element of HCV elimination and achieving this
may be one of the most difficult obstacles to overcome in
the elimination process.
This paper will describe (trends in) HCV epidemiology
in the Netherlands, the micro-elimination progress in
different HCV risk groups and also outline the strategies
that have been employed by different stakeholders to
improve uptake and retention in each step of the Dutch
HCV healthcare cascade. Finally, we will elaborate on
the Dutch progress towards nationwide HCV elimin-
ation and elucidate if the Netherlands may be among the
first countries to achieve this final ambition in the near
future.
Hepatitis C prevalence and incidence in the
Netherlands
Although it is generally accepted that the Netherlands is
a low prevalence region for HCV, only few studies have
ever been performed to ascertain its prevalence in the
general population. Two cross-sectional serosurveys in
1996 and 2007 calculated a national prevalence of 0.1%
and 0.3%, respectively [5, 6]. Of note, groups from HCV
endemic regions were considered underrepresented in
the ‘96 survey and therefore a higher proportion (70%)
of non-Dutch nationalities were included in the ‘07 sur-
vey. In 2012, Vriend et al. applied a different approach
(i.e. the Workbook method) to estimate HCV prevalence
in the Netherlands. The Workbook method incorporates
lowest and highest available risk group based prevalence
estimates which are subsequently multiplied by the
different population sizes to generate an absolute num-
ber of HCV infected individuals per risk group. This
study reported an estimated HCV seroprevalence of
0.22% which had been averaged from the lowest and
highest total estimate of 0.07% and 0.37% respectively
[7]. A recent update of this estimate, with more exten-
sively defined prevalence estimates in different migrant
populations, reported a 0.16% HCV seroprevalence in
the Netherlands in 2017, which is still very similar to the
older estimates from ‘96 and ‘07. This would correspond
to 23,000 anti-HCV positive individuals in the Netherlands
[8]. From a global perspective, it shows that the aforemen-
tioned HCV prevalence rate of 0.16% in the Netherlands is
not only among the lowest in Western Europe but also one
of the lowest worldwide [9–11]. Considering the HCV
prevalence in distinct risk groups, the Dutch situation to
some extent mimics the distribution in North America,
Western Europe, and Australia, meaning that HCV infec-
tion is hyper endemic among people who (ever) inject(ed)
drugs (PWID) (seroprevalence 39–74%) [12–16]. However,
ongoing viral transmission of hepatitis C in the Dutch
PWID group seems virtually non-existent: 44 cases of
acute HCV were reported nationwide in 2016 of which < 5
were associated with intravenous drug use [17]. This is in
line with the very low level of injecting among current drug
users (estimated to be less than 1000 drug injectors in the
whole country, with high access to clean injecting equip-
ment). Nevertheless, underreporting due to an asymptom-
atic disease course cannot be ruled out. The low HCV
incidence in PWID can also in part be explained by the
decline in injection drug use (IDU) after the problematic
1960–1970’s as a consequence of overall diminished
popularity but also due to the availability of physician-pre-
scribed methadone treatment, needle exchange and other
harm reduction programs [18, 19]. In 2015, the national
number of recent injecting drug users was historically low
(±500 i.e. 6% of all opiate users in addiction care) [20]. In
the Netherlands, the first generation migrants emerge
quantitatively as the major contributor to the Dutch na-
tional HCV burden (41–70%) [6–8]. However, the number
of new infections due to immigration is not considered to
have great impact on the total pool of chronically infected
since the annual Dutch population growth as a cause of
immigration is < 0.5% at the time of writing [21]. Also, the
HCV prevalence in migrant populations in different
nations has been described to be lower in comparison to
the country of origin prevalence estimates [22]. The
Netherlands, next to having a low prevalence, is also char-
acterized by a low incidence of HCV infections that are
mainly observed in the subgroup of HIV-infected persons
(49 acute HCV infections in HIV-infected in 2016, i.e. 5.5/
1000 person years, 95% CI 4.1–7.2). It was recently
reported that the Dutch incidence rate of acute HCV in
this group has decreased considerably, which is illustrative
of an effective “treatment as prevention” approach [23].
However, current re-infection rates in HIV-infected
(34/1000 person years in 2016) are still high and pre-
dominantly related to the involvement of men who
have sex with men (MSM) in high-risk sexual activ-
ities (including ‘chemsex’, i.e. sex under the influence
of psychoactive drugs) [24].
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Hepatitis C treatment effectiveness in different
subpopulations
Various Dutch subpopulations with increased risk and/
or prevalence of HCV can be identified as possible target
groups for micro-elimination: the ‘low risk population’,
migrants from high endemic countries, PWID, individuals
with HIV, prisoners, MSM, patients with hemophilia,
hemodialysis patients and health care workers (Table 1).
As mentioned previously, to determine the success of
HCV therapy uptake in subpopulations or otherwise
assess the HCV micro-elimination progress, adequate pa-
tient monitoring systems are essential. In the Netherlands,
several risk groups are closely monitored and (detailed)
information on HCV therapy uptake is available in sub-
populations such as HCV/HIV coinfected and HCV pa-
tients with an inherited bleeding disorder [24, 25]. With
regard to the Dutch HIV population, annual screening for
HCV infection is performed in those HIV positives in
treatment with ongoing risk factors / behavior, irrespective
of the presence of symptoms. Data from the Dutch HIV
monitoring foundation (SHM), that includes 98% of all
HIV-infected individuals who are retained in care, indi-
cated that virtually all patients (n = 1439; 96.6%) had been
screened at least once for HCV infection in 2017 [24]. Of
note, the number of undiagnosed HIV/HCV coinfections
is believed to be low (6% of the estimated 1750 undiag-
nosed Dutch HIV-infections) [24, 26]. Of those monitored
HCV/HIV coinfected patients, 76% had been cured by
February 2017 and from another 6% DAA therapy results
were pending, totaling more than 80% clearance rate for
this population [27]. Secondly, the van Creveldkliniek
hemophilia treatment center (University Medical Center
Table 1 Hepatitis C micro-elimination progress in target populations in the Netherlands in 2017
Population
size (N)
HCV
seroprevalence
(%)
Total chronic
HCV infections
(HCV RNA (+)) (N)
HCV infections
cured (N)/(%)
Source/Comments Main actions/interventions to
facilitate HCV elimination
HIV-infected 22,900 12% 1471 (R) 1124/76% [24, 27] • Behavioral counseling.
• Once in a lifetime or frequentc
screening (depending on
risk behavior).
Hemophilia patients
(born < 1992)
NA NA 700 (R) 190/27.1% [25] (Combined
Dutch & UK cohort)
• Once in a lifetime screening.
• Treatment scale-up.
High-risk MSM
(HIV-negative)b
NA 4,8% NA NA/NA [57] • Behavioral counseling.
• Frequentc screening
• Early treatment in case of (re) infection.
Migrants from high
endemic countries
1,527,032 NA 13,819 (E) NA/NA [58] • Raise awareness of HCV through local/
multimedia information campaigns.
• Once in a lifetime screening for
first-generation migrants with HCV
prevalence ≥2% in country of origin.
PWID 14,000 39–74% 4040–7666 (C) NA/NA [7, 12–16, 59] • Once in a lifetime or frequentc
screening (depending on risk behavior).
• Treatment scale up.
Prisoners 10,194/each day 7.4–13.9% 558–1049 (C) NA/NA [60–62] • Educate prison doctors on HCV.
• Once in a lifetime or frequentc
screening (depending on risk behavior).
• Include detainees in regular health
insurance.
Hemodialysis
patients
17,132 NA NA NA/NA [63] • Once in a lifetime screening.
Health care
workersd
NA NA NA NA/NA – • Once in a lifetime screening by employer.
General Dutch
population
17,081,507a 0.1–0.4% 12,640–50,561 (C) 4427/8–35% [7, 29] • Raise awareness of HCV through
multimedia information campaigns.
• Educate general practitioners on HCV
to increase compliance with viral hepatitis
screening and referral guidelines.
• Trace and treat HCV infected lost
to follow-up.
PWID people who (have ever) inject(ed) drugs, MSM men who have sex with men, NA not available. (R) = reported numbers from publications of
registries; (E) = estimated numbers reported in studies; (C) = calculated from seroprevalence estimates multiplied by .74 (assumed spontaneous
clearance rate of 26%)
a https://opendata.cbs.nl/statline/#/CBS/nl, Dutch population numbers in 2017
b MSM with high-risk sexual activities
c One to four times per year
d Health care workers who perform hazardous tasks, putting them at risk for acquiring of transferring a hepatitis C infection (definition from the
National Health Council) [4]
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Utrecht, The Netherlands) reported that 27% of all 700
chronic HCV patients with an inherited bleeding disorder
from a combined Dutch and UK cohort had been cured in
April 2012 [25]. This proportion of cured patients, like in
the HCV/HIV co-infected population, is expected to have
increased dramatically since DAA-therapy became
available.
Also, the transmission of HCV to hemophilia patients
due contaminated blood products has been halted with
the introduction of anti-HCV testing in blood donors
and of recombinant clotting factors [28]. Finally, data
obtained from the Drug Information System of the Na-
tional Health Care Institute (GIP) illustrate that between
the years 2009 until the availability of DAAs in 2015 an
estimated 4427 persons with HCV have been cured in
the Netherlands (i.e. 19% of the ±23,000 estimated HCV
antibody positive individuals) [29]. With regard to the
remaining HCV risk groups, exact data is lacking and no
reliable estimate of DAA therapy uptake in these sub-
populations could be made. A HCV prevalence estimate
was available in a number of groups (Table 1).
Dutch hepatitis C healthcare cascade: Strategies
towards micro-elimination
Awareness and prevention
A summary of the main Dutch strategies towards HCV
elimination is depicted in Fig. 1. In the Netherlands, sev-
eral institutions involved in public healthcare are dedi-
cated to increasing awareness and knowledge of HCV in
risk groups and as well as in the general population. To
this end, a large nation-wide multimedia HCV awareness
campaign was implemented in 2009/2010, targeting indi-
viduals attending methadone clinics and also risk groups
in the general population. In participating methadone
clinics HCV test uptake was 62% during the campaign.
At the end of the project, 257 additional HCV-carriers
had been identified in methadone clinic attendees and
the intervention was judged to be cost-effective in this
group. In contrast, the intervention was not cost-effect-
ive in the general population although the number of
anti-HCV tests in 25 laboratories had increased by
12.9% in comparison with previous years [30]. At the
annual Dutch National Hepatitis Day in November
2017, another compendious media campaign with both
radio and television broadcasts was launched by the
Dutch Liver Patient Association (NLV) to raise aware-
ness among patients, physicians but also health policy-
makers for the increasing Dutch mortality rates as a
cause of viral hepatitis [31]. This campaign has reached
over ten million persons in the Netherlands (personal
communication José Willemse, Executive director NLV).
Testing and diagnosis: Screening and retrieval projects
A key factor in achieving HCV elimination lies in aug-
menting the case finding rate. Case finding can be fur-
ther classified as: i) the identification of undiagnosed
HCV patients (i.e. screening) and ii) tracing of previously
diagnosed patients who are no longer in clinical care (i.e.
retrieval). Since migrants have been shown to account
for the majority of HCV infections in the Netherlands,
several large screening projects in migrant groups from
high endemic countries (a.o. Afghanistan, China, Egypt,
Iraq, Turkey, Poland) have been performed. The yield of
these projects however was low, despite the use of peers
in some projects, and only a handful of viremic HCV
(1–10 persons per project, i.e. 0.1–4.8%) were identified
of which also a small number was already aware of their
disease [32–38]. These low results could be explained by
a ‘healthy volunteer’ effect which indicates that the
participants of screening projects are in fact healthier
than the index population [39]. Further initiatives are
therefore still needed to encourage more individuals
with a migration background to get tested for HCV. This
is also supported by the Dutch National Health Council
(HC) who as of November 2016 recommends HCV
screening in all first generation migrant populations with
Fig. 1 Dutch HCV care cascade
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a known HCV prevalence in the country of origin of
≥2%. At the moment however, screening projects targeting
migrant populations at locations other than primary care
practices, require approval from the Ministry of Health,
Welfare and Sport (VWS) [4]. This prerequisite poses a
barrier for renewed screening efforts in migrant subgroups
(last project dates from 2013) in the present DAA-era in
which therapeutic options have improved immensely. Con-
sequently, HCV screening in first generation migrants cur-
rently falls under the responsibility of Primary Care
Physicians (PCPs) in the Netherlands who are guided by
their evidence-based professional ‘guideline on viral hepa-
titis’ from the Dutch College of General Practitioners
(NHG) [40]. The NHG guideline in addition promotes
screening in individuals with an increased ALT (≥1.5 times
the upper limit of normal) in the general population who
may have been at risk for HCV infection. However, due to
the small number of hepatitis patients in each PCP practice
and the limited knowledge on hepatitis, screening of hepa-
titis in PCP practices is suboptimal. Another subgroup with
high HCV prevalence (Table 1) deserving enhanced screen-
ing efforts is the detention population. Although the Dutch
Custodial Institution Agency introduced updated guidelines
on HCV screening in 2016, promoting HCV screening
upon confinement for those who have been at risk,
non-compliance with those guidelines occurs regularly and
the frequent relocation of detainees further complicates
treatment initiation and adherence. In addition, the Minis-
try of Justice finances the Dutch prison healthcare system
and reimbursing DAA-therapy poses a heavy burden on its
total health care budget. This constitutes another barrier
for testing and treating HCV-infected detainees.
Next to screenings projects, several retrieval projects
of diagnosed patients who have been lost to follow-up
have been executed in various regions in the Netherlands.
Projects were initiated by different physicians involved in
care for hepatitis patients: hospital based specialists
(Gastroenterology, Infectious Diseases and Microbiology),
PCPs, but also Public Health physicians. The most
commonly applied method in those retrieval projects was
the reevaluation of positive HCV diagnostics from the past
10–15 years from microbiological laboratories in order to
identify untreated patients. Patients with presumed
persistent HCV would then be reevaluated by their PCP
and, if appropriate, invited back into clinical care. The
proportion of chronic HCV patients who were lost to
follow-up was reported to be as high as 38% [41–43]. Re-
sults of the main (published) Dutch retrieval projects are
summarized in Fig. 3. The largest retrieval effort in the
center of the Netherlands (REACH-project) has been the
most successful thus far with 28.3% of all lost to follow-up
patients traced [44]. One of the success factors may be
that, in contrast to other endeavors, in the REACH-pro-
ject patients were invited directly at the outpatient clinic
without interference of the general practitioner. The
REACH-project served as a pilot and subsequent nation-
wide roll-out of HCV retrieval is scheduled to start in
2018 (CELINE). The CELINE initiative constitutes a
collaboration between hepatologists and Infectious dis-
eases physicians of all eight Dutch Academic Medical
Centers (HepNED) and aims to realize case ascertainment
in > 50% those who previously tested positive for HCV in
the next 3 years and also to include 95% of retrieved
patients in a national registry [45].
Linkage to care
The Dutch national plan on viral hepatitis underlined
the importance of regional, multi-stakeholder, healthcare
networks (i.e. hepatitis teams) in order to monitor and
safeguard the local identification and linkage to care of
HCV patients from all different risk group [2]. Such
hepatitis teams have been installed successfully in
various regions (Arnhem, Utrecht) and may serve as an
example for other districts [32]. The “Breakthrough Pro-
ject”, initiated by the Netherlands Institute of Mental
Health and Addiction (Trimbos Institute) is another
example of a collaborative between various stakeholders.
The Trimbos Institute aspired to structurally improve
the detection and linkage to care of HCV in Dutch
addiction care clinics and to develop sustainable HCV
referral cascades. To this end, two implementation pro-
jects based on the Breakthrough methodology (Break-
through Project) were initiated between 2013 and 2016.
Multiple multidisciplinary teams, including Gastroenter-
ology specialists from a (nearby) hepatitis treatment
center and nurses, medical doctors and managers from
the local addiction care center, created a local and sus-
tainable HCV referral pathway to secure linkage to care.
Final results of the project are pending.
Access to medication and qualified health services
In the Netherlands, virtually all patients have good
access to healthcare and also, once diagnosed with HCV,
to DAA therapy. As of November 2015, all available
DAAs are reimbursed by basic health care insurance
(which is obligatory in the Netherlands) irrespective of
fibrosis stage, alcohol or drug use status. Basic health-
care insurance in the Netherlands however includes
obligatory deductible excess, which added up to 385
euro per year in 2017 and 2018. This amount has to be
paid by the policy holder before an insurance providers
covers any expenses and may negatively affect one’s will-
ingness to get tested for HCV, especially in individuals
with lower socio-economic status. On average, the
obligatory deductible excess is fully spend by 50% of all
insured individuals annually [46]. As described previ-
ously, the Ministry of Justice pays DAA therapy costs for
individuals in detention. Asylum seekers can be considered
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for HCV treatment, but only when a residence permit is
granted.
Although a wide variety of stakeholders is involved in
the detection of and care for patients with a chronic
HCV infection in the Netherlands (Fig. 2), until now
treatment of HCV remains under the responsibility of
hospital-based-physicians (specialists in hepatology or in-
fectious diseases physicians working in designated hepa-
titis centers). There are 45 designated hepatitis centers in
the Netherlands (Fig. 3) which can all be attended to on
referral by the PCP. Physicians in all hepatitis treatment
centers can consult the Dutch national “guidebook” on
HCV treatment (www.HCVrichtsnoer.nl) that summa-
rizes the recommendations of the main international
guidelines on HCV treatment. The ‘HCV richtsnoer’ pro-
vides guidance for the appropriate DAA regimen selec-
tion with an update being published after each major
international guideline revision [47].
Monitoring and evaluation
Adequate monitoring and registration of all patients in
each step of the HCV healthcare cascade is essential to
achieve HCV elimination. When drop out at any of the
stages of the HCV healthcare cascade has been reduced
to zero, elimination will have been achieved. By the
Dutch public health act, in 1999 it became mandatory
to report acute HCV infections to the local Public
Health Services and hence incident infections are re-
corded since then. Until now, chronic HCV infections
do not require notification but this is about to change
in 2018. In addition, a pilot project was initiated in
2017 by the Dutch Association of Internal Medicine
(NIV) and Gastroenterology and Hepatology (NVMDL)
specialists with 8 participating hospitals aiming to cre-
ate a registry for treatment uptake and outcome of all
viral hepatitis B & C mono-infections. This project was
able to benefit from the existing registration system of
the HIV Monitoring Foundation (SHM) that has
already been used to monitor both HIV-mono and
HIV/hepatitis B or C co-infected patients for decades
[48]. The previously mentioned national retrieval pro-
ject CELINE aspires to further, both retrospectively and
prospectively, complete this registry in the upcoming
years.
The Dutch Central Bureau of Statistics (CBS) collects
data on the primary cause of death in the general popu-
lation and based on this information, the annual viral
hepatitis C and B related mortality was estimated at +/−
Fig. 2 Dutch HCV healthcare stakeholders
Kracht et al. Hepatology, Medicine and Policy  (2018) 3:12 Page 6 of 10
500 deaths per year between 2002 and 2015 [31]. The
viral hepatitis related mortality has not yet decreased as
a consequence of the introduction of DAA-therapy. The
van Creveldkliniek hemophilia treatment center reported
a mortality rate of 28% in patients with hemophilia and
chronic HCV of which 28% was liver-related (median
follow-up of 31 years since HCV infection) [25]. These
numbers however date from the pre-DAA era. The
SHM registers the cause of death in HIV mono- and
HIV/HCV coinfected however viral hepatitis related
mortality in HIV/HCV coinfected individuals has not
been explicitly described [24].
Fig. 3 All 45 hepatitis treatment centers in the Netherlands [41–44]
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Future direction for hepatitis C (micro-)
elimination in the Netherlands
The present Dutch situation with low HCV seropreva-
lence (0.1–0.4%) [7, 11] and a limited number of new
infections [17, 23] is an excellent starting point for final
HCV elimination. Some experts argue that the propor-
tion of undiagnosed or ‘hidden’ HCV patients may actu-
ally be smaller than previously estimated as exemplified
by a large high prevalence birth cohort screening project
in the South of the Netherlands (n = 3434 patients) that
did not identify any active HCV infections [49]. A study
modelling the future HCV burden of disease in the
Netherlands estimated an 85% reduction in chronic
HCV infections by the year 2030, if treatment rate can
be scaled up adequately [50]. In the past years, numerous
Dutch micro-elimination projects have consequently put
their efforts into enhancing the screening, linkage to care
and finally the HCV treatment uptake in various risk group
populations [27, 30, 32–35, 37, 38, 41–43]. Taking all en-
deavors into account, a drastic future reduction in the Dutch
pool of chronic HCV-infected can be envisioned.
Important caveats however do remain in various stages
of the Dutch HCV continuum of care which will have to
be addressed before HCV micro-elimination can be
achieved. First of all, the proportion of chronic HCV
patients who has been lost to follow-up is substantial
[41–43]. The nationwide roll out of the pilot project for
retrieval but also registration of viral hepatitis C
mono-infections (CELINE) therefore constitutes an im-
portant challenge to complete in the near future [45].
Secondly, as can be observed in the micro-elimination
table, data on exact prevalence and therapy uptake is still
unknown for many target groups (Table 1). The progress
against HCV can thus not be tracked appropriately.
When successfully executed, CELINE will substantially
contribute to overcoming this issue by entering the data
of > 95% of previously diagnosed HCV patients who
have been retrieved in a central registry. Thirdly, despite
the existence of various professional HCV screening
guidelines, current screening strategies do not adequately
target several high prevalence risk groups and a consider-
able group might still be unware of their disease. Specific
improvements have to be made in the identification and
linkage to care of HCV patients in addiction care centers,
those originating from high endemic HCV countries
immigrating to the Netherlands and also the general
population as they constitute the major contributors to
the Dutch HCV burden of disease (although overesti-
mation of the HCV prevalence cannot be ruled out) [7].
Also, HIV-negative MSM who engage in high-risk sexual
behavior (e.g. those receiving HIV Pre-Exposure Prophy-
laxis or PrEP) recently emerged as another subgroup with
a relatively high HCV incidence (0.7–1.3 per 100
person-years) [51–53]. In the SHM HIV/HCV coinfected
cohort, high DAA-therapy uptake of 76% has led to a
decrease in HCV incident infections by half (from 11.2 to
5.5 per 1000 person-years) but a substantial (re-) infection
rate remains [23]. Modeling studies describe that
behavioral counseling in addition to treatment scale-up
may be effective in further reducing the long-term HCV
prevalence [54, 55].
With the current diminishing prevalence, the upcom-
ing challenge will be to improve case finding strategies
in order to accomplish higher treatment rates and to
avoid a ‘diagnostic burn-out’ (i.e. the amount of treat-
ments is reduced to zero because patients remain
unware of their disease and therefore will not receive
therapy) [56]. This diagnostic endeavor is preferably
taken on by the PCPs as they encounter the majority of
the Dutch population at risk for HCV in their practices.
Since knowledge of HCV in Dutch PCPs is deemed
insufficient, focus should shift towards educating PCPs
about viral hepatitis C. With the current simplified DAA
therapy regimens, treatment of patients with none to
mild fibrosis may even be transferred to the PCPs in the
future.
Conclusion
The current Dutch HCV epidemiology with both low
prevalence and incidence in combination with universal
access to DAA therapy, favors a future HCV elimination
scenario. The micro-elimination method, that delivers tar-
geted interventions at pre-defined HCV risk groups, is fre-
quently applied to improve the Dutch HCV healthcare
cascade and constitutes a pragmatic and efficient approach.
To avoid an eventual diagnostic burn-out, efforts towards
case-finding should be intensified. Although challenges
remain, the Netherlands continues to be one of the
global frontrunners in its efforts to national viral
hepatitis C elimination. Whether this goal may actu-
ally be achieved by the year 2030, remains to be elu-
cidated in the next couple of years.
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